215 related articles for article (PubMed ID: 17536794)
21. Development of a high-throughput electrophysiological assay for the human ether-à-go-go related potassium channel hERG.
Gillie DJ; Novick SJ; Donovan BT; Payne LA; Townsend C
J Pharmacol Toxicol Methods; 2013; 67(1):33-44. PubMed ID: 23103595
[TBL] [Abstract][Full Text] [Related]
22. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
23. Functional characterization of the LQT2-causing mutation R582C and the associated voltage-dependent fluorescence signal.
Fougere RR; Es-Salah-Lamoureux Z; Rezazadeh S; Eldstrom J; Fedida D
Heart Rhythm; 2011 Aug; 8(8):1273-80. PubMed ID: 21376840
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the rubidium efflux assay for preclinical identification of HERG blockade.
Chaudhary KW; O'Neal JM; Mo ZL; Fermini B; Gallavan RH; Bahinski A
Assay Drug Dev Technol; 2006 Feb; 4(1):73-82. PubMed ID: 16506891
[TBL] [Abstract][Full Text] [Related]
25. Role of the pH in state-dependent blockade of hERG currents.
Wang Y; Guo J; Perissinotti LL; Lees-Miller J; Teng G; Durdagi S; Duff HJ; Noskov SY
Sci Rep; 2016 Oct; 6():32536. PubMed ID: 27731415
[TBL] [Abstract][Full Text] [Related]
26. Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity.
Zhou J; Augelli-Szafran CE; Bradley JA; Chen X; Koci BJ; Volberg WA; Sun Z; Cordes JS
Mol Pharmacol; 2005 Sep; 68(3):876-84. PubMed ID: 15976038
[TBL] [Abstract][Full Text] [Related]
27. Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting.
Huang XP; Mangano T; Hufeisen S; Setola V; Roth BL
Assay Drug Dev Technol; 2010 Dec; 8(6):727-42. PubMed ID: 21158687
[TBL] [Abstract][Full Text] [Related]
28. Correlation between human ether-a-go-go-related gene channel inhibition and action potential prolongation.
Saxena P; Hortigon-Vinagre MP; Beyl S; Baburin I; Andranovits S; Iqbal SM; Costa A; IJzerman AP; Kügler P; Timin E; Smith GL; Hering S
Br J Pharmacol; 2017 Sep; 174(18):3081-3093. PubMed ID: 28681507
[TBL] [Abstract][Full Text] [Related]
29. Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel.
Kang J; Chen XL; Wang H; Ji J; Cheng H; Incardona J; Reynolds W; Viviani F; Tabart M; Rampe D
Mol Pharmacol; 2005 Mar; 67(3):827-36. PubMed ID: 15548764
[TBL] [Abstract][Full Text] [Related]
30. Different relevance of inactivation and F468 residue in the mechanisms of hEag1 channel blockage by astemizole, imipramine and dofetilide.
Gómez-Varela D; Contreras-Jurado C; Furini S; García-Ferreiro R; Stühmer W; Pardo LA
FEBS Lett; 2006 Sep; 580(21):5059-66. PubMed ID: 16949586
[TBL] [Abstract][Full Text] [Related]
31. Inactivation gating determines drug potency: a common mechanism for drug blockade of HERG channels.
Yang BF; Xu DH; Xu CQ; Li Z; Du ZM; Wang HZ; Dong DL
Acta Pharmacol Sin; 2004 May; 25(5):554-60. PubMed ID: 15132818
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil.
Vicente J; Johannesen L; Mason JW; Crumb WJ; Pueyo E; Stockbridge N; Strauss DG
J Am Heart Assoc; 2015 Apr; 4(4):. PubMed ID: 25870186
[TBL] [Abstract][Full Text] [Related]
33. Removal of human ether-à-go-go related gene (hERG) K+ channel affinity through rigidity: a case of clofilium analogues.
Louvel J; Carvalho JF; Yu Z; Soethoudt M; Lenselink EB; Klaasse E; Brussee J; Ijzerman AP
J Med Chem; 2013 Dec; 56(23):9427-40. PubMed ID: 24224763
[TBL] [Abstract][Full Text] [Related]
34. Dofetilide block involves interactions with open and inactivated states of HERG channels.
Weerapura M; Hébert TE; Nattel S
Pflugers Arch; 2002 Feb; 443(4):520-31. PubMed ID: 11907818
[TBL] [Abstract][Full Text] [Related]
35. Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT.
Bridgland-Taylor MH; Hargreaves AC; Easter A; Orme A; Henthorn DC; Ding M; Davis AM; Small BG; Heapy CG; Abi-Gerges N; Persson F; Jacobson I; Sullivan M; Albertson N; Hammond TG; Sullivan E; Valentin JP; Pollard CE
J Pharmacol Toxicol Methods; 2006; 54(2):189-99. PubMed ID: 16563806
[TBL] [Abstract][Full Text] [Related]
36. Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade.
Deacon M; Singleton D; Szalkai N; Pasieczny R; Peacock C; Price D; Boyd J; Boyd H; Steidl-Nichols JV; Williams C
J Pharmacol Toxicol Methods; 2007; 55(3):238-47. PubMed ID: 17141530
[TBL] [Abstract][Full Text] [Related]
37. Novel intramolecular photoinduced electron transfer-based probe for the Human Ether-a-go-go-Related Gene (hERG) potassium channel.
Liu Z; Zhou Y; Du L; Li M
Analyst; 2015 Dec; 140(24):8101-8. PubMed ID: 26526230
[TBL] [Abstract][Full Text] [Related]
38. Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel.
Ridley JM; Milnes JT; Hancox JC; Witchel HJ
J Mol Cell Cardiol; 2006 Jan; 40(1):107-18. PubMed ID: 16288909
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the effects of DC031050, a class III antiarrhythmic agent, on hERG channel and three neuronal potassium channels.
Li P; Sun HF; Zhou PZ; Ma CY; Hu GY; Jiang HL; Li M; Liu H; Gao ZB
Acta Pharmacol Sin; 2012 Jun; 33(6):728-36. PubMed ID: 22609836
[TBL] [Abstract][Full Text] [Related]
40. Protein kinase A-mediated phosphorylation of HERG potassium channels in a human cell line.
Wei Z; Thomas D; Karle CA; Kathöfer S; Schenkel J; Kreye VA; Ficker E; Wible BA; Kiehn J
Chin Med J (Engl); 2002 May; 115(5):668-76. PubMed ID: 12133532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
